132 related articles for article (PubMed ID: 18451248)
1. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells.
Tatebe H; Shimizu M; Shirakami Y; Tsurumi H; Moriwaki H
Clin Cancer Res; 2008 May; 14(9):2806-12. PubMed ID: 18451248
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid.
Matsushima-Nishiwaki R; Okuno M; Takano Y; Kojima S; Friedman SL; Moriwaki H
Carcinogenesis; 2003 Aug; 24(8):1353-9. PubMed ID: 12807734
[TBL] [Abstract][Full Text] [Related]
3. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells.
Tatebe H; Shimizu M; Shirakami Y; Sakai H; Yasuda Y; Tsurumi H; Moriwaki H
Cancer Lett; 2009 Nov; 285(2):210-7. PubMed ID: 19520494
[TBL] [Abstract][Full Text] [Related]
4. Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells.
Baba A; Shimizu M; Ohno T; Shirakami Y; Kubota M; Kochi T; Terakura D; Tsurumi H; Moriwaki H
BMC Cancer; 2013 Oct; 13():465. PubMed ID: 24103747
[TBL] [Abstract][Full Text] [Related]
5. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells.
Kanamori T; Shimizu M; Okuno M; Matsushima-Nishiwaki R; Tsurumi H; Kojima S; Moriwaki H
Cancer Sci; 2007 Mar; 98(3):431-7. PubMed ID: 17270033
[TBL] [Abstract][Full Text] [Related]
6. Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand.
Ohno T; Shirakami Y; Shimizu M; Kubota M; Sakai H; Yasuda Y; Kochi T; Tsurumi H; Moriwaki H
Cancer Lett; 2012 Oct; 323(2):215-22. PubMed ID: 22579649
[TBL] [Abstract][Full Text] [Related]
7. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
8. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
Nakamura H; Takamori S; Fujii T; Ono M; Yamana H; Kuwano M; Shirouzu K
Cancer Lett; 2005 Dec; 230(1):33-46. PubMed ID: 16253759
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells.
Shimizu M; Suzui M; Deguchi A; Lim JT; Xiao D; Hayes JH; Papadopoulos KP; Weinstein IB
Clin Cancer Res; 2004 Oct; 10(19):6710-21. PubMed ID: 15475462
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
11. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells.
Obora A; Shiratori Y; Okuno M; Adachi S; Takano Y; Matsushima-Nishiwaki R; Yasuda I; Yamada Y; Akita K; Sano T; Shimada J; Kojima S; Okano Y; Friedman SL; Moriwaki H
Hepatology; 2002 Nov; 36(5):1115-24. PubMed ID: 12395321
[TBL] [Abstract][Full Text] [Related]
12. Combination of bevacizumab and acyclic retinoid inhibits the growth of hepatocellular carcinoma xenografts.
Kubota M; Shimizu M; Baba A; Ohno T; Kochi T; Shirakami Y; Moriwaki H
J Nutr Sci Vitaminol (Tokyo); 2014; 60(5):357-62. PubMed ID: 25744425
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.
Koay DC; Zerillo C; Narayan M; Harris LN; DiGiovanna MP
Breast Cancer Res; 2010; 12(4):R62. PubMed ID: 20696059
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines.
Bijman MN; van Berkel MP; Kok M; Janmaat ML; Boven E
Anticancer Drugs; 2009 Jul; 20(6):450-60. PubMed ID: 19369859
[TBL] [Abstract][Full Text] [Related]
16. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.
Wen XF; Yang G; Mao W; Thornton A; Liu J; Bast RC; Le XF
Oncogene; 2006 Nov; 25(52):6986-96. PubMed ID: 16715132
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
18. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.
Ding X; Qu X; Fan Y; Che X; Qu J; Xu L; Liu J; Liu Y
Anticancer Drugs; 2014 Mar; 25(3):315-22. PubMed ID: 24300914
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
